Home>>Signaling Pathways>> Angiogenesis>>Apatinib-d8

Apatinib-d8

Catalog No.GC49799

An internal standard for the quantification of apatinib

Products are for research use only. Not for human use. We do not sell to patients.

Apatinib-d8 Chemical Structure

Cas No.: 2468771-43-7

Size Price Stock Qty
1 mg
$103.00
In stock
5 mg
$465.00
In stock
10 mg
$775.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Apatinib-d8 is intended for use as an internal standard for the quantification of apatinib by GC- or LC-MS. Apatinib is a tyrosine kinase inhibitor that potently suppresses the kinase activity of vascular endothelial growth factor 2 (VEGFR2; IC50 = 1 nM).1 It is less effective against c-Kit (IC50 = 429 nM), RET (IC50 = 13 nM), and c-Src (IC50 = 53 nM) and does not inhibit EGFR, HER2, or FGFR1 (IC50s = >10 µM).1 Apatinib has been shown to inhibit the proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) stimulated by fetal bovine serum and, either alone or in combination with chemotherapeutic agents, prevents the growth of several established human tumor xenograft models.1

1.Tian, S., Quan, H., Xie, C., et al.YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivoCancer Sci.102(7)1374-1380(2011)

Reviews

Review for Apatinib-d8

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Apatinib-d8

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.